Anti-programmed Cell Death Receptor 1, Immune Checkpoint Inhibitors, Immunotherapy, Metastatic Cervical Carcinoma, Objective Response Rate, Persistent Cervical Carcinoma, Radiotherapy, Recurrent Cervical Carcinoma, Survival Outcomes, Tislelizumab
Conditions
Brief summary
This study is a prospective, multicenter, phase II clinical trial to evaluate the efficacy and safety of albumin-bound paclitaxel plus bevacizumab for platinum-resistant recurrent epithelial ovarian cancer. Patients with platinum-resistant recurrent ovarian cancer who meet the inclusion criteria, and don't meet any of the exclusion criteria, are enrolled in the study. They will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles. Treatment continue until disease progression, intolerable toxicity, or patient refusal. Objective response rates primary objective. Progression-free survival, overall survival, and safety are secondary objectives. The study will enroll a total of 50 patients.
Interventions
COMBINATION_PRODUCTTislelizumab plus radiotherapy
During the period of radiotherapy, patients receiveTislelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W). Tislelizumab 200mg q3W was administered for up to 35 cycles (up to approximately 2 years) after radiotherapy until disease progression or toxicity.
Sponsors
Lei Li
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The patient voluntarily participates and signs informed consent 2. Aged 18 years of age or older 3. Has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 within 7 days prior to the first dose of study treatment 4. Has recurrent cervical cancer and controllable local treatment, indicating an indication for radiation therapy 5. Willing to accept concurrent radiotherapy combined with Tislelizumab 6. Has measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the local investigator 7. Has adequate organ function 8. Has expected survival time ≥3 months
Exclusion criteria
1. Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), or with an agent directed to another stimulatory or co-inhibitory T-cell receptor 2. Has a known history of Human Immunodeficiency Virus (HIV) infection，active Hepatitis virus infection and active tuberculosis (TB; Bacillus tuberculosis) 3. Has known active central nervous system (CNS) metastases and/or uncontrolled, untreated carcinomatous meningitis with elevated intracranial pressure 4. Has received a major surgery within 4 weeks prior to signing informed consent 5. Not suitable for radiotherapy 6. Reassessment of liver and kidney function and blood routine indexes after radiotherapy did not meet the above criteria 7. Did not meet the other requirements for inclusion by the investigator 8. Judged unqualified of the enrollment requirements by the researcher according to other conditions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | 12 months | Overall survival is defined as the duration from date of enrollment to the date of death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | 12 months | PFS defined as the time the duration from date of enrollment to the first documented disease progression, or death due to any cause, whichever occurs first. |
| Overall survival | 24 months | Overall survival is defined as the duration from date of enrollment to the date of death from any cause |
| Adverse Events | 24 months | Adverse event (AE), Treatment emergent adverse event (TEAE), Serious adverse event (SAE) |
Countries
China
Contacts
Primary ContactLei Li, M.D.
Outcome results
None listed